Paroxysmal Atrial Fibrillation: Role of Inflammation, Oxidative Stress Injury and Effect of Statins (PAFRIOSIES)
Atrial Fibrillation
About this trial
This is an interventional prevention trial for Atrial Fibrillation focused on measuring atrial fibrillation, statin therapy, CRP levels, Paroxysmal Atrial Fibrillation
Eligibility Criteria
Inclusion Criteria: Patients with paroxysmal AF (> 3 epis each > 15 min in length) over 6 months Patients on stable antiarrhythmic drug therapy and life expectancy > 1 year Exclusion Criteria: Patients with PAF due to reversible cause Chronic inflammatory conditions Other medical conditions requiring statin therapy Patients on amiodarone or verapamil Elevated CK or ALT Life expectancy <1 year TAVN ablation Geographic isolation Inability to give informed consent
Sites / Locations
- University of Calgary, Foothills Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
1
2
Patients randomized to active drug, then AF burden and CRP values will be compared to those in placebo arm.
Patients take placebo once daily for 6 Months, then AF burden and CRP values will be compared to those in experimental arm.